

Press release

Ipsen announces its corporate agenda for 2008

Paris (France), 20 December 2007 - Ipsen (Euronext: FR0010259150; IPN) announces today its corporate agenda for 2008:

31 January 2008	Full year 2007 sales
27 February 2008	Full year 2007 results
29 April 2008	First quarter 2008 sales
4 June 2008	General shareholders' meeting
11 June 2008	Payment of 2007 dividend *
31 July 2008	First half 2008 sales
29 August 2008	First half 2008 results
30 October 2008	First nine months 2008 sales

* Depending on the approval of the Board of directors (26 February 2008) and of the General shareholders' meeting (4 June 2008)

About Ipsen

Ipsen is an innovation driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. The company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) which are growth drivers, and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The location of its four Research and Development centres (Paris, Boston, Barcelona, London) gives the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. In 2006, R&D expenditure was €178.3 million, i.e. 20.7% of consolidated sales, which amounted to €861.7 million while total revenues amounted to €945.3 million (in IFRS). 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen's shares are traded on Segment A of Eurolist by Euronext™ (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of the SBF 250 index. From 24 December 2007, the Group will be part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipsen.com.

For further information:

Didier Véron
Director, Public Affairs and Corporate Communications
Tel.: +33 (0)1 44 30 42 38
Fax: +33 (0)1 44 30 42 04
E-mail: didier.veron@ipsen.com

David Schilansky
Investor Relations Officer
Tel.: +33 (0)1 44 30 43 31
Fax: +33 (0)1 44 30 43 21
E-mail: david.schilansky@ipsen.com